(Q54630456)

English

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

0 references

1 reference

based on heuristic

inferred from title

author name string

K Tamura

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

C Shimizu

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

T Hojo

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

S Akashi-Tanaka

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

T Kinoshita

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

K Yonemori

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

T Kouno

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

N Katsumata

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

M Ando

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

K Aogi

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

F Koizumi

11

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

K Nishio

12

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

Y Fujiwara

13

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

publication date

25 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

22

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

1302-1307

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

Monoclonal antibody mechanisms of action in cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Mapping of the alpha-1,6-fucosyltransferase gene, FUT8, to human chromosome 14q24.3.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Highly parallel SNP genotyping

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Illumina universal bead arrays

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

A review of research methodology in an emergency medicine journal

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Correlation and Simple Linear Regression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ585

21 January 2018

Identifiers

10.1093/ANNONC/MDQ585

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21109570

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54630456&oldid=1561187019"